Skip to main content

Table 2 Lab investigations of the studied groups

From: Association between miR-196a2 polymorphism and the development of hepatocellular carcinoma in the Egyptian population

 Control
N = 60
Cirrhosis
N = 60
HCC
N = 80
Kruskal–WallisP valuePost hoc
AST(U/L)
 Min-max10.0–29.0012.0–226.0021.0-540.085.26< 0.001P1 = < 0.001
X ± SD17.30 ± 4.5060.56 ± 43.95124.26 ± 204.04P2 = 0.02
 Median17.0045.5068.50P3 = < 0.001
ALT(U/L)
 Min-max10.00–27.0011.0–121.0011.0–379.086.56< 0.001P1 = < 0.001
X ± SD18.01 ± 4.8175.30 ± 18.7379.32 ± 71.51P2 = < 0.63
 Median17.0054.0055.00P3 = < 0.001
Albumin (g/dL)
 Min-max3.70–5.01.0–4.002.0–4.0114.31< 0.001P1 = < 0.001
X ± SD4.42 ± 0.051.74 ± 0.092.62 ± 0.66P2 = 0.32
P3 = < 0.001
 Median4.403.003.00
Total bilirubin (mg/dl)
 Min-max.20–.801. 2-15.01.0–20.00  P1 = < 0.001
X ± SD0.267 ± 0.0213.20 ± 0.4133.45 ± 0.38121.93< 0.001P2 = 0.31
 Median.541.203.0P3 = < 0.001
Direct bilirubin (mg/dl)
 Min-max.06–.201.00–11.001.00–16.0051.30< 0.001P1 = < 0.001
X ± SD0.038 ± 0.0043.22 ± 0.903.33 ± 0.37P2 = 0.30
 Median.1051.001.50P3 = < 0.001
Alpha fetoprotein (ng/mL)
 Min-max-------1-1006-20,9499.78*< 0.001----------
X ± SD 13.85± 1.783770.10 ± 421.51
 Median 4.00526.00
Prothrombin conc.
 Min-max83–10040–9319-102112.96< 0.001P1 = < 0.001
X ± SD93.67 ± 4.53456.63 ± 13.46758.37 ± 16.95P2 = 0.87
 Median92.5050.6057.40P3 = < 0.001
PT.INR
 Min-max1.00–1.111.02–1.83.95–3.59113.35< 0.001P1 = < 0.001
X ± SD1.03 ± 0.0281.42 ± 0.181.48 ± 0.434P2 = 0.65
 Median1.02001.431.38P3 = < 0.001
 No%No%No%   
HCV Ab
 Negative60100.011.778.8167.15< 0.001 
 Positive00.05998.37391.2
HBV sAg
 Negative60100.060100.07897.51.96**0.33 
 Positive00.000.022.5
  1. *Mann–Whitney test
  2. **Fisher’s exact test
  3. • P1 = comparison between cirrhosis and control
  4. • P2 = comparison between cirrhosis and HCC
  5. • P3 = comparison between control and HCC